The HDAC4 Knockout NCI-H1975 Polyclonal Cells product consists of a heterogeneous CRISPR/Cas9-edited knockout cell population derived from the parental NCI-H1975 line, with targeted disruption of the HDAC4 gene. This loss-of-function model allows for the study of HDAC4-dependent processes, including histone deacetylase activity and transcriptional control, without the need for clonal isolation.
The parental NCI-H1975 cell line is a well-characterized model of EGFR-mutant non-small cell lung cancer (NSCLC), originally established from a lung adenocarcinoma. These epithelial cells harbor both L858R and T790M mutations in the EGFR kinase domain, conferring oncogenic signaling and resistance to first-generation tyrosine kinase inhibitors. This genetic background makes the knockout model particularly relevant for investigating tumor progression and therapeutic responses in advanced lung adenocarcinoma.
HDAC4 is a class IIa histone deacetylase that represses transcription by deacetylating histone lysine residues on histones H3 and H4, as well as non-histone substrates such as the tumor suppressor p53. Its activity is regulated through phosphorylation by CaMKII/IV, AMPK, and PKA, which promotes 14-3-3 binding and nuclear export, thereby modulating its interaction with transcription factor MEF2. Within transcriptional repressor complexes containing HDAC3 and SMRT/NCoR, HDAC4 mediates silencing of MEF2 target genes, including myogenin and GLUT4, and also influences p53 acetylation status and TGF-?? signaling.
In the context of NCI-H1975 cells, loss of HDAC4 is expected to disrupt these repressive complexes, leading to derepression of MEF2-regulated genes and altered p53 transactivation potential. This may influence cell survival, differentiation, and stress responses, pathways often dysregulated in EGFR-driven lung adenocarcinoma. The polyclonal population approach maintains cellular heterogeneity, permitting the study of phenotypic variations associated with HDAC4 disruption without clonal selection bias and enabling robust assessment of drug sensitivity, particularly to HDAC inhibitors.
This knockout model is suited for a wide range of applications, including mechanistic studies of HDAC4 in EGFR-mutant NSCLC, analysis of MEF2 target gene derepression via RT-qPCR and RNA-seq, and examination of p53 acetylation dynamics using immunoprecipitation and Western blotting. Functional assays such as apoptosis, migration/invasion, and HDAC inhibitor sensitivity testing can be combined with reporter assays for MEF2 transcriptional activity. Additionally, co-immunoprecipitation and ChIP-qPCR can be employed to map altered protein interactions and chromatin modifications. Researchers can leverage this tool to investigate drug resistance mechanisms and to validate HDAC4 as a therapeutic target. For additional information or technical support, please contact Ascent Research.
